
Evaluating Chest Pain Approaches and controversies

ZACHARY HARTSELL, MHA, PA-C



Learning Objectives

Upon conclusion of this lecture, the participant will be able to:

1. Describe cardiac vs. non-cardiac chest pain
2. Discuss risk stratification for patients with suspected cardiac chest pain
3. Explore appropriate and optimal testing for both cardiac and non-cardiac etiologies of chest pain
4. Review the treatment of common causes of chest pain
5. Avoid having chest pain while evaluating chest pain patients

Cardiac Chest Pain

Myocardial ischemia

- ACS
- Stable angina

Aortic dissection

Pericarditis

Myocarditis

Pericardial tamponade

Heart failure

Arrhythmia

Mr. N

68-year-old male with HTN, HLD, GERD, and ongoing tobacco abuse presents to the ED with substernal chest pain.

He describes the pain as “tightness and pressure”, which began two hours ago while sitting at his desk. The pain lasted an hour and radiated to his left shoulder and arm. He is currently pain-free.

Mr. N

On exam:


- BP 145/87 (R) 141/85 (L), HR 74, RR 16, O₂ 99% RA
- General → WDWN. NAD. A&Ox3.
- Heart → RRR without MRG.
- Lungs → CTA B/L.
- Abdomen → +BS. Soft. ND. NT.
- Extremities → Peripheral pulses 2+ B/L. No pedal edema B/L.

What is your differential diagnosis?

Chest Pain

More than **eight million** visits to the ED each year with acute chest pain

- Less than 10% of these have ACS



Features With Increased Probability of MI

Table 2. Value of Specific Components of the Chest Pain History for the Diagnosis of Acute Myocardial Infarction (AMI)

| Pain Descriptor | Reference | No. of Patients | Positive Likelihood Ratio (95% CI) |
|--|-----------|-----------------|------------------------------------|
| Increased likelihood of AMI | | | |
| Radiation to right arm or shoulder | 29 | 770 | 4.7 (1.9-12) |
| Radiation to both arms or shoulders | 14 | 893 | 4.1 (2.5-6.5) |
| Associated with exertion | 14 | 893 | 2.4 (1.5-3.8) |
| Radiation to left arm | 24 | 278 | 2.3 (1.7-3.1) |
| Associated with diaphoresis | 24 | 8426 | 2.0 (1.9-2.2) |
| Associated with nausea or vomiting | 24 | 970 | 1.9 (1.7-2.3) |
| Worse than previous angina or similar to previous MI | 29 | 7734 | 1.8 (1.6-2.0) |
| Described as pressure | 29 | 11 504 | 1.3 (1.2-1.5) |
| Decreased likelihood of AMI | | | |
| Described as pleuritic | 29 | 8822 | 0.2 (0.1-0.3) |
| Described as positional | 29 | 8330 | 0.3 (0.2-0.5) |
| Described as sharp | 29 | 1088 | 0.3 (0.2-0.5) |
| Reproducible with palpation | 29 | 8822 | 0.3 (0.2-0.4) |
| Inframammary location | 31 | 903 | 0.8 (0.7-0.9) |
| Not associated with exertion | 14 | 893 | 0.8 (0.6-0.9) |

Abbreviations: AMI, acute myocardial infarction; CI, confidence interval.

Differential Diagnosis

| | Critical | Less Critical |
|------------------|--------------------------------------|---|
| Cardiac | ACS, aortic dissection | Pericarditis, myocarditis |
| Pulmonary | PE, pneumothorax | Pneumonia, pleurisy, pleural effusion |
| Gastrointestinal | Esophageal rupture, perforated ulcer | GERD, esophageal spasm, esophagitis, PUD, cholecystitis |
| Musculoskeletal | - | Costochondritis, rib fracture, cervical stenosis |
| Dermatologic | - | Herpes zoster |
| Psychiatric | - | Anxiety, panic attack |

Thinking Outside the Box...

Acute chest
syndrome
(sickle cell anemia)

Trauma


Referred pain

Precordial catch
syndrome

Substance abuse

Collagen vascular disease

Herpes zoster



Diagnostic Approach


Step 1: Rule out critical conditions

- ACS → urgent ECG!
- Aortic dissection
- PE

Step 2: Risk stratify patients for cardiac etiology

Step 3: Evaluate for less critical conditions

Mr. N




Mr. N's Labs

13.9
7.0 / 39.5 \ 241
4.1 | 19 | 0.8
139 | 116 | 18.2 / 94

| | Mr. Sullivan | Reference Range |
|------------|--------------|-----------------|
| Troponin T | <0.010 | <0.010 |

- ECG, CXR, and one set of cardiac enzymes are normal.
- What do you do next?



High-Sensitivity Troponin T (hs-cTnT)

5th generation

Has been used in Europe for years and now FDA approved for use in the US

High-sensitivity assays for hs-cTnT can detect levels as low as 5ng/L.

hs-cTnT \neq the current Troponin T

- The values should not be compared.
- hs-cTnT can detect lower levels.
- Shorter time intervals between repeat values
 - Possible intervals: 0, 2, and 6 hours

How to Interpret the Values (ng/L)

Whole numbers not decimals

Normal or elevated - not negative or positive

99th% upper limit normal

- Male: 15 ng/L
- Female: 10 ng/L

| Deltas from Time 0 | |
|--------------------|--|
| 2h Δ | ≤ 3 = unchanged 4-9 = intermediate ≥ 10 = Changing |
| 6h Δ | $\geq 12+$ = Changing |

Risk Stratification

Heart Score

Timi

TIMI Risk Score

Variables

- Age ≥ 65 years
- \geq three risk factors for CHD
- Prior coronary stenosis of ≥ 50 percent
- ST segment deviation on admission ECG
- \geq two anginal episodes in prior 24 hours
- \uparrow serum cardiac biomarkers
- Aspirin use in prior seven days

TIMI Risk Score

↑ TIMI risk score =
↑ numbers of events at 14 days

All-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring revascularization

| Score | Risk % |
|-------|--------|
| 0-1 | 4.7 |
| 2 | 8.3 |
| 3 | 13.2 |
| 4 | 19.9 |
| 5 | 26.2 |
| 6-7 | 40.9 |

HEART Score

- Useful to evaluate undifferentiated chest pain in the ED

| | 0 points | 1 point | 2 points |
|-----------------|-----------------------|--|---|
| History | Incompatible with ACS | Potentially compatible with ACS | Strongly suggestive of ACS |
| ECG | Normal | Nonspecific repolarization abnormalities | ST depression or transient ST elevation |
| Age | <45 | 45-65 | >65 |
| Risk Factors | None | 1-2 Risk Factors | 3 Risk Factors or known CAD |
| Troponin Levels | Normal | 1-3x upper limit of normal | >3x upper limit of normal |

HEART Score

Predicts 6 week risk of major adverse cardiac event (MACE)

- Risk of missed ACS <1%

| Score | Risk | Recommendation |
|-------|---------------|-----------------------|
| 0-3 | Low Risk | Outpatient follow up |
| 4-6 | Moderate Risk | Admission to hospital |
| 7 | High Risk | Admission to hospital |

Back to Mr. N

HEART score = **6**


- History: potentially compatible with ACS **(1)**
- ECG: nonspecific repolarization abnormalities **(1)**
- Age: >65 **(2)**
- Risk Factors: at least three risk factors **(2)**

HEART Pathway

Combines the HEART score and serial cardiac troponins

Low risk score < 4

High Risk score ≥ 4



Mr. N

You admit Mr. N for observation and he is given ASA. He is monitored on cardiac telemetry overnight and has no recurrent chest pain.

A stress test is planned for the following morning...

Inpatient Stress Testing

Exercise or pharmacologic stress ↑ myocardial oxygen demand and reveals an inadequate oxygen supply (hypoperfusion) in diseased coronary arteries

Mixed data inpatient vs. outpatient

? low risk patients

Poor outpatient compliance

Modalities of Stress Testing

Exercise ECG: simple, widely available, low cost

- Many limitations, but may be appropriate initial test in some

Stress Echocardiography: localizes ischemia, provides structural information, fast results

- Limited utility with resting RWMA's

Stress Radionuclide Myocardial Perfusion Imaging (rMPI):

- Can quantify involved myocardium and assess viability, good for known CAD
- More expensive, radiation exposure, longer interpretation times; limited utility with balanced ischemia (3-vessel disease)

Coronary CT Angiography

Low to intermediate risk patients with normal ECG and negative troponins who have potential ACS

- **Sensitivity = 94%, Specificity = 83%**

*for focal lesions of >70% stenosis when compared with invasive coronary angiography

Potential benefits: reduce unnecessary testing, decrease LOS, cost

Back to Mr. N

He underwent stress myocardial perfusion imaging. Per his RN, he tolerated the procedure well. He is anxious to discharge .

No myocardial ischemia or infarction.

Mild dilation of left ventricle with mild degree global hypokinesis.
Post-stress LVEF at 46%.

HISTORY: Chest pain. Coronary artery disease. Status post stent placement.

STRESS STUDY: At baseline, blood pressure was 144/87, with a heart rate of 65 beats per minute. Oxygen saturation was 96%.



Balanced ischemia

ACS Treatment

- MONA is no more...



ACS Treatment

Step 1: Immediate therapy for ACS

- **ASPIRIN**
- **NITRATES**
 - IV Nitroglycerin for persistent ischemic pain, HF, or HTN
- **ANALGESICS**
 - **Morphine** used only when other anti-anginals at maximum dose are not relieving CP
 - **NSAIDS** should be discontinued/not initiated because of risk of MACE
- **OXYGEN**
 - Used for respiratory distress, oxygen saturation <90%
 - “Hyperoxia” has been shown to have a direct vasoconstrictor effect on coronary arteries

ACS Treatment

Step 1: Immediate therapy for ACS

- **P2Y12 INHIBITORS**
 - **Clopidogrel** 300-600mg loading dose
 - **Ticagrelor** 180mg loading dose
 - ***Prasugrel** 60mg loading dose
- Load at time of presentation vs. PCI (risk vs. benefit)
 - Does your patient potentially need CABG?

ACS Treatment

Step 1: Immediate therapy for ACS

- **PARENTERAL ANTICOAGULATION THERAPY:**
 - **Unfractionated Heparin (UFH):** continued for 48 hours or until PCI performed
 - **Enoxaparin (LMWH):** for duration of hospitalization or until PCI performed
 - **Fondaparinux (Factor Xa inhibitor):** for duration of hospitalization or until PCI performed
 - Not used as sole anticoagulant
 - **Bivalirudin (Direct thrombin inhibitor):** 0.10 mg/kg loading with 0.25 mg/kg per hour until PCI
 - Similar outcomes to UFH, but less cost effective

ACS Treatment

Step 2: Decide on a treatment strategy

- **STEMI**: FMC to device time expected to be ≤ 90 minutes
- **NSTE-ACS**: Ischemia guided vs. early invasive strategy

Ischemia-guided vs. Early Invasive Strategy

Ischemia-guided Strategy

- Only calls for an invasive evaluation if:
 - patient fails medical therapy (refractory angina)
 - objective evidence of ischemia (dynamic ECG changes, perfusion defect)
 - clinical indicators of very high prognostic risk (e.g. high TIMI or GRACE scores)

Early Invasive Strategy (within 24 hours)

- Triages patients to an invasive diagnostic evaluation (i.e. coronary angiogram)
 - Generally a high-risk patient, or with high-risk features (e.g. + troponin)

Irrespective of strategy chosen, a patient receives optimal anti-ischemic and anti-thrombotic medical therapy

ACS Treatment

Step 3: Institute routine medical therapy

- **Beta Blockers**: within 24 hours unless contraindicated
- **Statins**: high intensity, regardless of baseline LDL-C
- **ACE/ARB**: LVEF<40%, HTN, DM, stable CKD
- **Aldosterone Antagonist**: if already on therapeutic ACE, BB, and have an LVEF<40%
- **Calcium Channel Blockers**: no benefit; consider only if recurring ischemia, or BB and nitrates are contraindicated or maximized

Mrs. P

48 YO F with asthma, microcytic anemia 2/2 menorrhagia
2/2 uterine fibroids presents to the ED with DOE X 4 weeks
and R shoulder and chest pain X 4 days.

Mrs. P

Vitals:

- T 36.5 C; HR 117 bpm; BP 150/94 mmHg; RR 24 br/min; SpO2 95% RA


Labs:

| | | |
|-------|------|-----|
| 9.8 | 8.9 | 421 |
| ----- | | |
| | 30.9 | |


| | | | |
|-------|-----|------|-----|
| 135 | 103 | 16.5 | 143 |
| ----- | | | |
| 4.5 | 19 | 0.7 | |

hs-cTnT: 5 ng/L (female \leq 10 ng/mL)
NT-Pro BNP: 6,204 pg/mL (<248 pg/mL)
D-Dimer: 5,924 ng/mL (< 500 ng/mL*)

Ms. P Chest X-ray



Admission ECG (no priors)




(Modified) Wells Score for PE

| Criteria | Scoring |
|---|---------|
| Clinical symptoms of DVT | 3.0 |
| Other diagnosis less likely than PE | 3.0 |
| HR >100 | 1.5 |
| Immobilization \geq 3 days or surgery in the previous 4 weeks | 1.5 |
| Previous DVT/PE | 1.5 |
| Hemoptysis | 1.0 |
| Malignancy | 1.0 |

| Wells Criteria | Score |
|----------------|------------|
| High | >6.0 |
| Moderate | 2.0 to 6.0 |
| Low | <2.0 |

| Modified Wells Criteria | Score |
|-------------------------|------------|
| PE likely | >4.0 |
| PE unlikely | \leq 4.0 |

CTPA



PE Treatment

Step 1: If PE suspected, stabilize the patient while definitive diagnostic test is ongoing


- IV Heparin v. Low Molecular Weight Heparin

Step 2: Risk stratification

- High-risk/massive
- Intermediate-risk/submassive
- Low-risk/small

Hemodynamic instability (“massive PE”): SBP < 90 mmHg for > 15 minutes, hypotension requiring vasopressors, or clear evidence of shock

Massive PE Treatment



Hemodynamically Stable PE

Treat with anticoagulation unless contraindicated:

- Consider IVC Filter
- Consider risk vs. benefit

Consider **thrombolysis** or **catheter-directed thrombolysis** on a case-by-case basis:

- Severe RV dysfunction
- Extensive DVT
- Presence of severe hypoxemia
- Patients who appear to be decompensating but not yet hypotensive
- Clot in transit (RA or RV clot)

Back to Mrs. P

Transthoracic Echocardiogram:

Final Impressions

1. Findings consistent with cor pulmonale - possibly acute.
2. Moderate right ventricular enlargement with moderate-severe systolic dysfunction (FAC 26%).
3. Estimated right ventricular systolic pressure 93 mmHg (systolic blood pressure 170 mmHg).
4. Tricuspid annulus dilatation with moderate-severe functional tricuspid regurgitation.
5. Severely dilated inferior vena cava with no inspiratory collapse and dilated hepatic veins.

Underwent emergent **catheter-directed thrombolysis**

Mrs. P

At 24 hours → catheter pulled and placed on heparin drip

- COMPLETE resolution of symptoms!

Transitioned to Xarelto upon discharge

- IUD placed for her vaginal bleeding

Mr. S

65 YO M with untreated HTN presents to the ED with acute onset of dizziness and severe chest pain with radiation to his back, of acute onset while he was in the shower. He also described bilateral 9/10 flank pain and nausea & emesis.

Mr. S

Vitals:

- T 37 C; HR 78; BP 189/99; RR 20 br/min; 96% RA

Labs:


| | | |
|------|------|-----|
| 11.4 | 14.7 | 175 |
| | 42.4 | |

| | | | |
|-----|-----|-----|-----|
| 143 | 108 | 17 | 104 |
| 4.1 | 26 | 0.9 | |

hs-cTnT: 8 ng/L (male \leq 15 ng/L)

D-dimer: 1,208 ng/mL (< 500 ng/mL*)

Admission ECG



Chest X-Ray



Mr. S

You are called to see the patient in the ED, so you quickly review his records from when he was admitted to the hospital with atypical chest pain 1 month prior...

TTE (one month prior):

Final Impressions

1. Normal left ventricular chamber size. Hyperdynamic left ventricular systolic function.
2. Calculated 2-D monoplane volumetric left ventricular ejection fraction 73 %.
3. Mid left ventricular maximal instantaneous Doppler gradient rest 6 mm Hg; Valsalva 28 mm Hg.
4. Concentric remodeling (increased wall thickness to cavity ratio).
5. Findings consistent with normal left ventricular filling pressure.
6. Mild right ventricular enlargement with normal systolic function.
7. Normal left atrial size.
8. No hemodynamically significant valvular heart disease.
9. Normal inferior vena cava size with normal inspiratory collapse (>50%).
10. Mild ascending aorta dilatation (diameter 41 mm at proximal level).
11. No pericardial effusion.

ECG and CXR are unchanged.

ADD-RS

Aortic Dissection Detection Risk Score (ADD-RS):


1. **High risk conditions:** Marfan syndrome or other CT disease, aortic valvular disease, family history/gene mutation, known thoracic aortic aneurysm, previous cardiac surgery or aortic manipulation

1. **High risk features:** pain in the chest back or abdomen that is abrupt, severe, or a ripping/tearing sensation

1. **High risk PE findings:** pulse deficit, SBP difference, focal neurologic deficit, aortic diastolic murmur, shock

Score 0-3 based on the presence of any positives in each of the categories

- low risk = 0
- intermediate risk = 1
- high risk = 2-3



CT Angiography Chest



Mr. S

CT Angio Chest

CONCLUSION:

1. Type B aortic dissection in the mid descending thoracic aorta with slow flow in the false lumen and intramural hematoma extending into the abdominal aorta. Please see dedicated abdominal CT for detailed intra-abdominal findings.

Management of Aortic Dissection

If hypotension or shock:

- IVF bolus +/- vasopressors
- Surgical consultation
- Review/additional imaging studies
 - **Severe AR? Cardiac tamponade?**

If stable, IV labetalol preferred




- Maintain HR <60, SBP <120 mmHg

Pain control is essential

- IV morphine reduces force of cardiac contraction

Dissections involving the **ascending thoracic aorta** should have urgent operative or interventional management if able

Classification of aortic dissection

| | | | |
|------------|---|---|---|
| |  |  |  |
| Percentage | 60% | 10–15% | 25–30% |
| Type | DeBakey I | DeBakey II | DeBakey III |
| | Stanford A (Proximal) | | Stanford B (Distal) |

Back to Mr. S

Admitted to the ICU, started on esmolol drip + nicardipine drip

Vascular Surgery consult: recommended conservative management and serial imaging studies

Complicated hospital course, eventually discharged hospital day 5 on the following regimen:

- labetalol 400mg TID
- lisinopril 40mg QD
- amlodipine 10mg QD
- chlorthalidone 25mg QD

Take Home Points

It is helpful to differentiate cardiac vs. non-cardiac chest pain.

Keep a wide differential...chest pain does not always mean ACS.

Use risk stratification tools, but despite these tools, your clinical judgement is most important!

Swap CJ, Nagurney JT. Value and Limitations of Chest Pain History in the Evaluation of Patients With Suspected Acute Coronary Syndromes. *JAMA*.2005;294(20):2623-2629.

Long B, Oliver J, Streitz M, et al. An End User's Guide to the HEART Score and Pathway. *Am Journ Emerg Med*. 2017;35(9):1350-1355.

Arbab-Zadeh A. Stress testing and non-invasive coronary angiography in patients with suspected coronary artery disease: time for a new paradigm. *Heart International*. 2012;7(1):e2.

Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *J Am Coll Cardiol*. 2010;56(25):e50-e103

Nieman K, Hoffmann U. Cardiac computed tomography in patients with acute chest pain. *Eur Heart J*. 2015 Apr 14; 36(15): 906–914

Hoffmann U, Truong QA, Schoenfeld DA, et al. Coronary CT angiography versus standard evaluation in acute chest pain. *N Engl J Med*. 2012;367:299-308.

Budoff MJ, Dowe D, Jollis JG, Gitter M, Sutherland J, Halamert E, et al. Diagnostic performance of 64-multidetector row coronary computed tomographic angiography for evaluation of coronary artery stenosis in individuals without known coronary artery disease: results from the prospective multicenter ACCURACY (Assessment by Coronary Computed Tomographic Angiography of Individuals Undergoing Invasive Coronary Angiography) trial. *J Am Coll Cardiol*. 2008;52(21):1724–32. doi: [10.1016/j.jacc.2008.07.031](https://doi.org/10.1016/j.jacc.2008.07.031).

Tweet MS, Arruda-Olson AM, Anavekar NS, et al. Stress Echocardiography: What Is New and How Does It Compare with Myocardial Perfusion Imaging and Other Modalities? *Current Cardiology Reports*. 2015;17:43.

Litt HI, Gatsonis C, Snyder B, et al. CT angiography for safe discharge of patients with possible acute coronary syndromes. *N Engl J Med*. 2012;366:1393-403.

Hoffmann U, Bamberg F, Chae CU, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. *J Am Coll Cardiol*. 2009;53:1642-50.

Pickering J, Than M, Young J, et al. Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection: A Collaborative Meta-analysis. *Annals Of Internal Medicine* [serial online]. April 18, 2017; Available from: MEDLINE Complete, Ipswich, MA.

Garg P, Morris P, Fazlanie AL, et al. Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. [Intern Emerg Med](https://doi.org/10.1007/s11739-017-1612-1). 2017; 12(2): 147–155. doi: [10.1007/s11739-017-1612-1](https://doi.org/10.1007/s11739-017-1612-1)

Hofmann R, James SK, Jernberg T, et al. Oxygen Therapy in Suspected Acute Myocardial Infarction. *N Engl J Med*. 2017;377(13):1240.

Moradkhan R, Sinoway LI. Revisiting the role of oxygen therapy in cardiac patients. *J Am Coll Cardiol*. 2010;56(13):1013.

Meine TJ, Roe MT, Chen AY, Patel MR, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. *Am Heart J*. 2005 Jun;149(6):1043-9.

Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. *Eur Heart J*. 2016;37(3):245.

Freund Y, Cachanado M, Aubry A. Effect of the Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients: The PROPER Randomized Clinical Trial. *JAMA*. 2018;319(6):559.

Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. *Circulation*. 2014;129:479–486.

Piazza G, Hohlfelder B, Jaff MR, et al. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: The SEATTLE II study. *JACC Cardiovasc Interv*. 2015;8:1382–1392.

Mangi MA, Rehman H, Bansal V. Ultrasound Assisted Catheter-Directed Thrombolysis of Acute Pulmonary Embolism: A Review of Current Literature. *Cureus*. 2017 Jul; 9(7): e1492. doi: [10.7759/cureus.1492](https://doi.org/10.7759/cureus.1492)

Nazerian P, Mueller C, Soeiro AM, et al. Diagnostic Accuracy of the Aortic Dissection Detection Risk Score Plus D-Dimer for Acute Aortic Syndromes: The ADVISED Prospective Multicenter Study. *Circulation*. 2018;137(3):250.

Hiratzka LF, Bakris GL, Beckman JA, et al. Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease: ACC/AHA Pocket Guideline: March 2010. Accessed July 26, 2018.